Prime medicine reports fourth quarter and full year 2022 financial results and provides business update

-- announced preclinical data providing further proof-of-concept for prime editing's ability to achieve restoration of genetic function, as well as new preliminary safety analyses demonstrating no detected off-target activity -- -- nominated pm359, first development candidate for the treatment of chronic granulomatous disease (cgd) --
PRME Ratings Summary
PRME Quant Ranking